ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

It is estimated that there are currently about 17.2 million individuals with diabetes mellitus in the US, of which type 2 diabetes accounts for 90−95% of cases. Individuals with diabetes are at high risk of developing hypertension, heart disease, stroke, myocardial infarction (MI) and other complications. Furthermore, the risk of cardiovascular death is two- to three-fold higher among women with diabetes versus those without diabetes, and three- to four-fold higher among men with versus without diabetes. Consequently, reducing the risk of such events, and the related costs, among individuals with diabetes is a pertinent issue for healthcare payers in the US. Ramipril is one of the most potent long-acting ACE-inhibitors available, and has been shown to be effective for treating all grades of hypertension and heart failure. The cost effectiveness of ramipril treatment among patients with diabetes is therefore of great interest to healthcare professionals in the US. Similarly, the risk of cardiovascular (CV) events and death is high among patients who undergo percutaneous coronary intervention (PCI) for stable angina pectoris. The benefits of ramipril therapy among these patients have been shown in large clinical trials, and the favourable cost effectiveness of such therapy will enhance its worth among certain patient populations. These issues were examined in two studies presented at the 52nd Annual Scientific Session of the American College of Cardiology [Chicago, US; March/April 2003]

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Solifenacin succinate [YM 905], an investigational long-acting antimuscarinic agent, is effective and well tolerated in patients with overactive bladder, according to results from three phase III studies presented at the Annual Meeting of the American Urological Association [Chicago, US; April−May 2003]. These studies, involving more than 2000 patients, showed that solifenacin succinate significantly reduced urinary urgency, incontinence and frequency, compared with placebo. More than half of the patients treated with solifenacin succinate became continent by the end of the study. Another important finding was that the increase in the volume of each micturition among patients treated with solifenacin succinate was 3−6 times that observed in placebo recipients."Solifenacin succinate may give physicians another option to help... patients cope with the embarrassing and bothersome symptoms of incontinence that severely impact on quality of life",said Dr Joel Kaufman from Urology Research Options in Aurora, US.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS